Zhuhai Meihua Medical Technology
Provides information and intelligence services for corporate marketing departments
About Zhuhai Meihua Medical Technology
Zhuhai Meihua Medical Technology Co., Ltd., established in 2007, is a high-tech enterprise specializing in the field of in-vitro diagnostic (IVD) instruments and reagents. Initially the liquid-based product division of Shanghai Angbai Biomedical Technology Co., Ltd., the company now operates as a wholly-owned subsidiary. The firm is focused on providing comprehensive solutions for clinical microbiology laboratories. Its business strategy centers on developing products with independent intellectual property rights to achieve both "technical substitution" and "import substitution" within the Chinese market.
The company's clientele includes thousands of hospitals, laboratories, and scientific research institutions. Its products are distributed in over 40 countries and regions, demonstrating a significant international footprint. The business model involves the research and development, manufacturing, sales, and service of its diagnostic systems and consumables. Meihua has received venture capital backing, including a Series B funding round of $13.9 million in November 2022.
Meihua's product portfolio is extensive, featuring over 30 types of in-vitro diagnostic instruments and reagents across six main series. A cornerstone of their offering is the MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) microbial mass spectrometry system for rapid microorganism identification. Other key products include automated microbial identification and antibiotic susceptibility testing (ID/AST) systems, automatic blood culture analysis systems, and a range of microbiological culture media and laboratory automation equipment. These systems are designed to provide rapid, accurate, and cost-effective detection of a wide array of microorganisms, such as bacteria and fungi, to aid in the clinical diagnosis of conditions like bloodstream infections.
The company's research and development team is composed of scientists and clinical doctors from international institutions, including the Mayo Medical Center and Yale University School of Medicine. This has enabled the company to secure over 40 patents and receive numerous accolades for its products, with 22 being recognized as "Guangdong High-tech Products". The firm's stated mission is to become a distinguished global brand in the testing field by providing precise, comprehensive solutions for microbial detection.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Marketing
- Business model
- SaaS
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2022 | $14M | $55M | Sunland fund · Zhuhai High-tech Gold Investment · Humble Capital · Eight Roads Ventures | ↗ |
| ANGELEquity / VC | Sep 2007 | $399K | $1.6M | Biochem Group · Oriental Fortune Capital · TEDA Venture Capital | — |
Growth signals
Latest recorded traffic for Zhuhai Meihua Medical Technology is 410 monthly website visits, down 43.1% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhuhai Meihua Medical Technology in its local ecosystem
The Zhuhai Meihua Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- BGBiochem Group
Oriental Fortune Capital- TCTEDA Venture Capital
Series A4 investors entered at this stage
Sunland fund- ZIZhuhai High-tech Gold Investment
- HCHumble Capital
Eight Roads Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhuhai Meihua Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhuhai Meihua Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







